FDA Approves Unknown Drug — HIBROW HLTHCARE

# FDA Approves New Generic Drug Application for Hibrow Healthcare Hibrow Healthcare has received FDA approval for its abbreviated new drug application (ANDA 207611), positioning the company to capture market share in an established therapeutic segment and potentially intensifying price competition in the category. The approval expands Hibrow's generic portfolio and strengthens its competitive standing in the pharmaceutical market.